Anthera Pharma (ANTH) Says Pre-Specified Primary Endpoint Wasn't Met in Phase2b PEARL-SC Dose Ranging Study of Blisibimod

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/17/2026

1. SPY
2. EYPT
3. NVDA
4. GNK
5. AZN
6. SPCX
7. FNGR
8. PLUR
9. USO
10. HIVE

Go back to Anthera Pharma (ANTH) Says Pre-Specified Primary Endpoint Wasn't Met in Phase2b PEARL-SC Dose Ranging Study of Blisibimod
ANTHERA PHARMA (AMEX: ANTH) Delayed: 0.00 --0 (-0%)
Previous Close $0.00    52 Week High $6.08 
Open $0.00    52 Week Low $1.72 
Day High $0.00    P/E 0.00 
Day Low $0.00    EPS $-1.47 
Volume 340